Completed PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT01993576

ICG Distribution Using NIF Imaging After IV Injection of ICG in Benign and Malignant Breast Cancer Tissue. (EC2075)

Histological Study of the (Intravenously Injected) ICG Distribution in Tumor Bearing Breasts and in Axillary Pieces of Dissection.

Sponsor: Jules Bordet Institute

Conditions Breast Cancer.

Interventions Indocyanine Green

Updated 5 times since 2017 Last updated: Oct 14, 2014 Started: Jan 31, 2013 Primary completion: Sep 30, 2014 Completion: Sep 30, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on Breast Cancer., this trial is completed. The trial is conducted by Jules Bordet Institute and has accumulated 5 data snapshots since 2013. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1_PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1_PHASE2

First recorded

Jan 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Jules Bordet Institute

Data source: Jules Bordet Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Brussels, Belgium